AzurRx BioPharma Reports Positive Interim P-II Data of MS1819 + PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

May 14, 2021 Auto Bot Clinical Trials, Cystic fibrosis, P-II, Pharma, Severe 0

Shots:

  • The interim data from 18 patients out of 20 in P-II trial evaluating the safety, tolerability, and efficacy of MS1819 (700/1200/2240 mg, qd, for 15 days/dosing level) + PERT aged 12 yrs or older in CF patients for EPI
  • The 1EP & 2EP of the trial demonstrated improvement in CFA, improvement in stool weight, stool consistency, bowel movements, rate of steatorrhea & increased body weight, reduced the symptoms of EPI, improved QoL with safety profile. The results from all 20 patients enrolled in the trial are expected in Q2′ 21
  • The company expects to enrol ~24 CF patients with severe EPI and the study completion is expected in Q1’ 21

Click here to­ read full press release/ article | Ref: GLOBE NEWSWIRE| Image: AzurRx BioPharma

The post AzurRx BioPharma Reports Positive Interim P-II Data of MS1819 + PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency first appeared on PharmaShots.